Cue Biopharma (CUE) Debt to Equity (2022 - 2025)

Cue Biopharma has disclosed Debt to Equity across 4 years of filings, most recently posting $0.12 for Q3 2025.

• Debt to Equity for Q3 2025 came in at $0.12, down 40.35% year-over-year; the trailing twelve-month figure through Sep 2025 was $0.12 (down 40.35% YoY), and the FY2024 annual result was $0.25, up 12.47% from the prior year.
• Debt to Equity came in at $0.12 for Q3 2025 at Cue Biopharma, down from $0.14 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.51 in Q1 2025 to a low of $0.12 in Q3 2025.
• The 4-year median for Debt to Equity is $0.21 (2024), against an average of $0.22.
• Peak annual rise in Debt to Equity reached 113.72% in 2025, while the deepest fall reached 50.64% in 2025.
• Cue Biopharma's Debt to Equity stood at $0.15 in 2022, then soared by 44.64% to $0.22 in 2023, then advanced by 12.47% to $0.25 in 2024, then slumped by 49.75% to $0.12 in 2025.
• The last three Debt to Equity figures came in at $0.12 (Q3 2025), $0.14 (Q2 2025), and $0.51 (Q1 2025), per Business Quant data.